UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 116

Sortiert nach

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors

Clinical cancer research, 2021-09, Vol.27 (17), p.4685-4689

2021

Link zum Volltext

Verfügbarkeit prüfen

Seamless Oncology-Drug Development

The New England journal of medicine, 2016-05, Vol.374 (21), p.2001-2003

2016

Link zum Volltext

Verfügbarkeit prüfen

Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health

The oncologist (Dayton, Ohio), 2021-10, Vol.26 (10), p.e1786-e1799

2021

Link zum Volltext

Verfügbarkeit prüfen

U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab

Clinical cancer research, 2017-07, Vol.23 (14), p.3484-3488

2017

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer

Clinical cancer research, 2020-08, Vol.26 (16), p.4180-4185

2020

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

Clinical cancer research, 2021-04, Vol.27 (7), p.1850-1854

2021

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer

Clinical cancer research, 2021-05, Vol.27 (9), p.2378-2382

2021

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen

Clinical cancer research, 2017-12, Vol.23 (24), p.7448-7453

2017

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma

Clinical cancer research, 2017-10, Vol.23 (19), p.5666-5670

2017

Link zum Volltext

Verfügbarkeit prüfen

Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice

The Journal of clinical investigation, 2010-11, Vol.120 (11), p.3953-3968

2010

Link zum Volltext

Verfügbarkeit prüfen

The Drug-Dosing Conundrum in Oncology — When Less Is More

The New England journal of medicine, 2021-10, Vol.385 (16), p.1445-1447

2021

Link zum Volltext

Verfügbarkeit prüfen

IL-15 Enhances the in vivo Antitumor Activity of Tumor-Reactive CD8+T Cells

Proceedings of the National Academy of Sciences - PNAS, 2004-02, Vol.101 (7), p.1969-1974

2004

Link zum Volltext

Verfügbarkeit prüfen

US Food and Drug Administration regulatory updates in neuro-oncology

Journal of neuro-oncology, 2021-07, Vol.153 (3), p.375-381

2021

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Clinical cancer research, 2019-02, Vol.25 (4), p.1142-1146

2019

Link zum Volltext

Verfügbarkeit prüfen

Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma

JHEP reports, 2023-06, Vol.5 (6), p.100747-100747, Article 100747

2023

Link zum Volltext

Verfügbarkeit prüfen

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis

The lancet oncology, 2020-02, Vol.21 (2), p.250-260

2020

Link zum Volltext

Verfügbarkeit prüfen

Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients

Journal of clinical oncology, 2022-10, Vol.40 (30), p.3489-3500

2022

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer

Clinical cancer research, 2020-03, Vol.26 (6), p.1208-1212

2020

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma

Clinical cancer research, 2021-04, Vol.27 (7), p.1836-1841

2021

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

Clinical cancer research, 2021-02, Vol.27 (4), p.922-927

2021

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma

Clinical cancer research, 2022-05, Vol.28 (9), p.1759-1764

2022

Link zum Volltext

Verfügbarkeit prüfen

Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

Cancer research (Chicago, Ill.), 2010-08, Vol.70 (15), p.6171-6180

2010

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

Clinical cancer research, 2021-09, Vol.27 (17), p.4680-4684

2021

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1

Clinical cancer research, 2020-05, Vol.26 (10), p.2284-2289

2020

Link zum Volltext

Verfügbarkeit prüfen

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions

Clinical cancer research, 2021-10, Vol.27 (20), p.5452-5456

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 116

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(109)
Mit Volltextzugriff
(102)

Publikationsform

Artikel
(115)
Buchkapitel
(1)

Sprache

Englisch
(116)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

Science & Technology
(94)
Life Sciences & Biomedicine
(93)
Humans
(71)
Oncology
(69)
United States
(32)
Drug Approval
(26)
Male
(26)
United States Food And Drug Administration
(26)
Adult
(25)
Female
(24)
Aged
(20)
Middle Aged
(20)
Immunotherapy
(17)
Animals
(15)
Cancer
(15)
Fda Approval
(14)
Metastasis
(14)
Aged, 80 And Over
(13)
Patients
(13)
Antineoplastic Agents - Therapeutic Use
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors

Seamless Oncology-Drug Development

Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health

U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab

FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer

FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer

FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen

FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma

Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice

The Drug-Dosing Conundrum in Oncology — When Less Is More

IL-15 Enhances the in vivo Antitumor Activity of Tumor-Reactive CD8+T Cells

US Food and Drug Administration regulatory updates in neuro-oncology

FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis

Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients

FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer

FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma

FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma

Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions

Suchergebnisse filtern